Early Dynamics of Circulating Tumor DNA Following Curative Hypofractionated Radiotherapy Related to Disease Control in Lung Cancer DOI Creative Commons
Kyungmi Yang, Jae Myoung Noh, Yeon Jeong Kim

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(10), P. 1198 - 1198

Published: May 9, 2025

Background/objectives: We aimed to characterize the dynamic pattern of circulating tumor DNA (ctDNA) during hypofractionated radiation therapy (RT) in patients with lung cancer and assess its clinical relevance. Metholds: Prospectively, 24 diagnosed early-stage underwent curative RT 60–64 Gy 4–20 fractions. Blood samples were collected at baseline (D0) on post-RT days 1–3 7 (D1–3 D7). The ctDNA was longitudinally analyzed using LiquidSCAN. To find a feasible index associated outcome, total VAF(%), max GE (hGE/mL) (hGE/mL), evaluated. Results: Thirteen available median 22.2-month follow-up (range, 5.2–34.3 months). Four experienced progression between 7.9 16.6 months after (PD group), nine presented no evidence disease (NED group). Dmax, day highest level among D0–7, significantly different groups (p = 0.035 0.021, respectively). According ROC curves, showed best AUC (86.1%) cut-off value Dmax 1.5 (sensitivity: 66.7%, specificity: 100%, positive-predictive value: negative-predictive 57.1%). Tumor size ≥ 3 cm, squamous histology, daily dose 3–4 correlated D2–3. better control rate marginal significance 0.081). Conclusions: timing early elevation may have potential predict response. be an verify levels RT.

Language: Английский

Early Dynamics of Circulating Tumor DNA Following Curative Hypofractionated Radiotherapy Related to Disease Control in Lung Cancer DOI Creative Commons
Kyungmi Yang, Jae Myoung Noh, Yeon Jeong Kim

et al.

Diagnostics, Journal Year: 2025, Volume and Issue: 15(10), P. 1198 - 1198

Published: May 9, 2025

Background/objectives: We aimed to characterize the dynamic pattern of circulating tumor DNA (ctDNA) during hypofractionated radiation therapy (RT) in patients with lung cancer and assess its clinical relevance. Metholds: Prospectively, 24 diagnosed early-stage underwent curative RT 60–64 Gy 4–20 fractions. Blood samples were collected at baseline (D0) on post-RT days 1–3 7 (D1–3 D7). The ctDNA was longitudinally analyzed using LiquidSCAN. To find a feasible index associated outcome, total VAF(%), max GE (hGE/mL) (hGE/mL), evaluated. Results: Thirteen available median 22.2-month follow-up (range, 5.2–34.3 months). Four experienced progression between 7.9 16.6 months after (PD group), nine presented no evidence disease (NED group). Dmax, day highest level among D0–7, significantly different groups (p = 0.035 0.021, respectively). According ROC curves, showed best AUC (86.1%) cut-off value Dmax 1.5 (sensitivity: 66.7%, specificity: 100%, positive-predictive value: negative-predictive 57.1%). Tumor size ≥ 3 cm, squamous histology, daily dose 3–4 correlated D2–3. better control rate marginal significance 0.081). Conclusions: timing early elevation may have potential predict response. be an verify levels RT.

Language: Английский

Citations

0